NYSE · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · LARGE CAP
McKESSON Corporation MCK
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY13 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$403.4B
▲ 12.4% vs FY2024
Dividend streak
13 yrs
Raised every year since 2013
EPS · FY25
$38.38
Dividend / sh · FY25
$3.17
Payout · FY25
8%
ROE · FY25
—
Net margin · FY25
1.2%
Dividend coverage
12.1×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 403.4B
Revenue, FY2025 · full 19-year series below
Revenue
Net income
1 cents of every revenue dollar became profit this year.
Per share
USD 38.38
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 12.1 times — the rest stayed in the company.
Profitability
—
Return on equity, FY2025
ROE
Operating margin1.5%
Net margin1.2%
Return on assets6.0%
Returned to shareholders
USD 5.1B
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 381.0M
Net buybacksUSD 4.8B
Share of profit107.7%
Consecutive raises13 years
USD 381.0M in dividends and USD 4.8B in buybacks — 108% of the year's profit, so the payout drew on cash built up earlier.
Growth
+11.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+13.4%
+11.1%
+7.8%
+8.9%
Net income
+10.2%
+7.7%
+9.6%
EPS, diluted
+15.3%
+14.7%
+15.2%
Dividend / share
+14.9%
+13.7%
+11.4%
+10.4%
Returned to shareholders
+9.3%
+38.2%
+10.7%
+7.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 82.3B
total assets, end of FY2025
Total assetsUSD 82.3B
EquityUSD -2.2B
CashUSD 4.0B
Gross debtUSD 6.5B
Net debtUSD 2.6B
Current ratio0.85×
Net debt stands at -117% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
403.4
359.1
309.0
276.7
264.0
238.2
231.1
214.3
208.4
198.5
190.9
179.0
137.4
122.2
122.3
112.1
108.7
106.6
101.7
Operating income $B
6.2
4.4
3.9
4.4
2.0
−5.0
2.5
0.9
0.8
7.1
3.5
3.0
2.4
2.3
2.1
1.8
2.0
1.2
1.5
EBITDA $B
6.5
4.7
4.2
4.7
2.4
−4.7
2.8
1.2
1.1
7.4
3.8
3.3
2.6
2.5
2.3
2.0
2.2
1.3
1.6
Income tax $B
1.1
0.9
0.6
0.9
0.6
−0.7
0.0
0.4
−0.1
1.6
0.9
0.8
0.8
0.6
0.5
0.5
0.6
0.2
0.5
Net income $B
4.8
3.3
3.0
3.6
1.1
−4.5
0.9
0.0
0.1
5.1
2.3
1.5
1.3
1.3
1.4
1.2
1.3
0.8
1.0
EPS, diluted $
38.38
25.72
22.39
25.03
7.23
−28.26
4.95
0.17
0.32
22.73
9.70
6.27
5.41
5.59
5.59
4.57
4.62
2.95
3.32
Dividend / sh $
3.17
2.75
2.40
2.09
1.83
1.67
1.62
1.51
1.30
1.12
1.08
0.96
0.92
0.80
0.80
0.72
0.48
0.48
0.24
Payout %
8
10
10
8
25
−6
33
859
391
5
11
15
17
14
14
14
10
14
7
ROE %
·
·
·
·
·
−179.0
13.7
0.4
0.6
50.7
26.7
17.9
16.2
19.3
20.0
16.3
18.4
13.3
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
74 of 74
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed